Ipamorelin
Adults after bowel resection · Hospital phase 2 trial · Beck 2014
Ipamorelin is a ghrelin-receptor agonist studied after bowel surgery. The selected trial used IV infusions. Adults after bowel resection · Hospital phase 2 trial · Beck 2014.
Reviewed 2026-10-17. A source reference, not a personal treatment plan. Discuss treatment decisions with a qualified clinician.
Dose reference
| STUDY CONTEXT | Dose | Frequency | Context |
|---|---|---|---|
| Postoperative trial arm | 0.03 mg/kg | Twice daily | IV; postoperative day 1–7 or until hospital discharge. Source |
An inpatient IV dose is not a SubQ growth-hormone or recovery protocol. This study does not validate combining ipamorelin with CJC-1295.
Source context
The randomised trial examined recovery of gastrointestinal function after bowel surgery. It found no significant difference from placebo in the key and secondary efficacy analyses.
Reading the dose correctly
An inpatient IV dose is not a SubQ growth-hormone or recovery protocol. This study does not validate combining ipamorelin with CJC-1295.
Download the chart
Further reading
Ipamorelin monograph on myPeptides
References
Does the reference apply to other formulations?
Only the product, preparation and route named here are covered. A shared substance name does not establish an equivalent amount for another formulation.
Where can I read the wider evidence?
The linked myPeptides Ipamorelin monograph covers the mechanism, human and preclinical evidence, and important distinctions between related substances.